Medications containing semaglutide, a GLP-1 receptor agonist, have become central to obesity management. These drugs regulate blood sugar, appetite, and body weight. Clinical data shows they reduce body weight by an average of 15 percent over 68 weeks when combined with lifestyle changes. The mechanism involves acting on the brain to increase fullness and decrease hunger.
Despite these averages, the drugs do not work uniformly for every patient. A multidisciplinary team at the University of Alberta is investigating why some individuals respond better than others. Their research aims to improve obesity care for all ages by understanding how weight loss is maintained over time.
Metabolic Adaptation and Energy Use
Energy metabolism is a key factor in treatment outcomes. This process measures total calories consumed versus total calories burned. The body burns energy continuously for vital functions like breathing, physical activity, and digestion.

When patients lose weight, their bodies naturally require less energy. However, the body often enters an energy-saving mode. This phenomenon, known as metabolic adaptation or adaptive thermogenesis, causes the body to burn fewer calories than expected. Researchers compare this to a light bulb that automatically dims to save electricity. This adaptation can lead to weight-loss plateaus, making further progress difficult.
Changes in body composition also influence this process. Both fat and fat-free mass consume energy, even at rest. As these tissues decrease during weight loss, the body’s overall calorie burn drops. Researchers are currently studying whether weight-loss medications influence these metabolic processes differently across individuals.

Research Methods and Participant Recruitment
The University of Alberta utilizes a whole-room indirect calorimeter to measure energy utilization. This facility, described as similar to a hotel suite, precisely measures each component of energy use. It isolates the effects of changes in calorie burning at rest, after eating, and during exercise.
The team is currently recruiting participants with blood sugar regulation issues, such as insulin resistance or diabetes, who are about to start semaglutide treatment. The study will follow their weight loss journey over six months. Researchers will use sophisticated approaches to track changes in body weight, composition, and energy utilization.
A recent review of studies on GLP-1 therapies found that findings on how semaglutide affects resting energy use were neutral or inconclusive. The question of how the drug impacts energy use remains an open area of study. Understanding these interactions could help explain individual response differences.

Better knowledge of how energy use changes with semaglutide-induced weight loss will help anticipate potential non-responders. This allows healthcare providers to offer alternative treatments sooner. The goal is to contribute to more personalized approaches to obesity and Type 2 diabetes management. Current evidence suggests that patients should make specific lifestyle changes alongside their medication.
Source: ScienceDaily

